Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma - PubMed (original) (raw)
Comparative Study
. 2001 Jan-Feb;8(1):115-8.
doi: 10.3892/or.8.1.115.
Affiliations
- PMID: 11115581
- DOI: 10.3892/or.8.1.115
Comparative Study
Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma
D O Hasselmann et al. Oncol Rep. 2001 Jan-Feb.
Abstract
Reverse transcription polymerase chain reaction (RT-PCR)-based detection of tyrosinase mRNA is a frequently used method for the identification of circulating tumor cells in melanoma patients. The significance and practical value of this procedure for the diagnosis of tumor dissemination in melanoma patients are unclear. The conflicting results may at least partially be related to very low amounts of circulating tumor cells and to our observation that melanoma cells only transiently persist in the peripheral blood. The purpose of the present study was to evaluate the relevance of detection of extracellular melanoma-specific mRNA in serum and plasma samples in comparison to blood cell samples from patients with disseminated disease (stage IV). We therefore compared the presence of specific mRNA for tyrosinase, gp100, and MART-1 by RT-PCR amplification of specific cDNA from serum, plasma, and whole blood samples of 10 melanoma patients. Melanoma-specific mRNA was detectable in whole blood samples of all ten patients tested indicating the presence of circulating melanoma cells. In addition, tyrosinase mRNA could be detected in the serum and/or plasma of 6 of 10 melanoma patients whereas gp100 and MART-1 specific transcripts were not detectable in any of the samples tested. The presence and integrity of amplifiable RNA was shown in all serum and plasma samples of patients and controls by RT-PCR-specific amplification of porphobilinogen deaminase (PBDG) mRNA. We conclude that tyrosinase mRNA but not gp100 and MART-1 mRNA can be amplified from serum and/or plasma in a subset of melanoma patients showing circulating melanoma cells. Therefore, extracellular-directed assays appear to be less sensitive and efficacious in detecting melanoma-specific transcripts compared to cellular-based assays.
Similar articles
- Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
de Vries TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, de Rooij MJ, Mensink EJ, Ruiter DJ, van Muijen GN. de Vries TJ, et al. Br J Cancer. 1999 May;80(5-6):883-91. doi: 10.1038/sj.bjc.6690436. Br J Cancer. 1999. PMID: 10360670 Free PMC article. - gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients.
Tsukamoto K, Ueda M, Hirata S, Osada A, Kitamura R, Takahashi T, Ichihashi M, Shimada S. Tsukamoto K, et al. J Dermatol Sci. 2000 Jun;23(2):126-31. doi: 10.1016/s0923-1811(99)00098-5. J Dermatol Sci. 2000. PMID: 10808130 - Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction.
Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, Scheibenbogen C, Heufelder K, Eggermont A, Thiel E. Keilholz U, et al. Clin Cancer Res. 2004 Mar 1;10(5):1605-12. doi: 10.1158/1078-0432.ccr-0610-3. Clin Cancer Res. 2004. PMID: 15014010 - Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients.
Schittek B, Blaheta HJ, Ellwanger U, Garbe C. Schittek B, et al. Recent Results Cancer Res. 2001;158:93-104. doi: 10.1007/978-3-642-59537-0_9. Recent Results Cancer Res. 2001. PMID: 11092036 Review. - Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, Napolitano M, Caracò C, Mozzillo N, Melucci MT, Cossu A, Tanda F, Gallo C, Satriano RA, Castello G. Palmieri G, et al. J Clin Oncol. 2003 Mar 1;21(5):767-73. doi: 10.1200/JCO.2003.01.128. J Clin Oncol. 2003. PMID: 12610172 Review.
Cited by
- EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages.
Mohammed N, Rodriguez M, Garcia V, Garcia JM, Dominguez G, Peña C, Herrera M, Gomez I, Diaz R, Soldevilla B, Herrera A, Silva J, Bonilla F. Mohammed N, et al. Oncol Lett. 2011 Jul;2(4):719-724. doi: 10.3892/ol.2011.294. Epub 2011 Apr 28. Oncol Lett. 2011. PMID: 22848255 Free PMC article. - Lung cancer screening: from imaging to biomarker.
Xiang D, Zhang B, Doll D, Shen K, Kloecker G, Freter C. Xiang D, et al. Biomark Res. 2013 Jan 16;1(1):4. doi: 10.1186/2050-7771-1-4. Biomark Res. 2013. PMID: 24252206 Free PMC article. - Issues and prospects of microRNA-based biomarkers in blood and other body fluids.
Chevillet JR, Lee I, Briggs HA, He Y, Wang K. Chevillet JR, et al. Molecules. 2014 May 14;19(5):6080-105. doi: 10.3390/molecules19056080. Molecules. 2014. PMID: 24830712 Free PMC article. Review. - cfRNAs as biomarkers in oncology - still experimental or applied tool for personalized medicine already?
Kolenda T, Guglas K, Baranowski D, Sobocińska J, Kopczyńska M, Teresiak A, Bliźniak R, Lamperska K. Kolenda T, et al. Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):783-792. doi: 10.1016/j.rpor.2020.07.007. Epub 2020 Aug 11. Rep Pract Oncol Radiother. 2020. PMID: 32904167 Free PMC article. Review. - Serum messenger RNA as a biomarker and its clinical usefulness in malignancies.
Miura N, Hasegawa J, Shiota G. Miura N, et al. Clin Med Oncol. 2008;2:511-27. doi: 10.4137/cmo.s379. Epub 2008 Sep 22. Clin Med Oncol. 2008. PMID: 21892326 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical